Phase-3 Studies of Welchol on Anti-diabetic Activity Kanthal LK1,*, Mondal P1, Vaswani L2, Mahanti B1 1Bharat Technology, Banitabla, Howrah, W.B, India 2Calcutta Institute of Pharmaceutical Technology and AHS, Uluberia, Howrah, India *Corresponding Author: L.K Kanthal Bharat Technology, Banitabla, Howrah, W.B, India. E: mail: lkkhaldia@gmail.com
Online published on 20 March, 2013. Abstract Diabetes is a condition primarily defined by the level of hyperglycaemia giving rise to risk of macro and micro vascular complication and diminished quality of life. Roman physician Areataeus was introduced the name diabetes in 1st century A.D. Diabetes treatment include a number of drugs either can be used alone or in combination. The present articles concentrate on the phase -3 studies of Welchol as an adjunct to Metformin in type –ll diabetes who are not responding to other combination of anti-diabetic drugs. Top Keywords Diabetes, Hyperglycaemia, complications, Welchol. Top |